CEMQ:F:F-iShares Edge MSCIope Quality Factor UCITS (EUR)

ETF | Others |

Last Closing

USD 10.802

Change

+0.11 (+1.05)%

Market Cap

USD 0.48B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+2.60 (+0.47%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.60 (+1.15%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.64 (+1.14%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.31 (+2.02%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

+0.83 (+0.85%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.40 (+0.60%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

-0.04 (-0.59%)

USD 41.48B
0ZC:F Zscaler Inc

+12.10 (+6.94%)

USD 37.92B
BSND:F Danone SA

+0.40 (+2.92%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing CEMQ:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.89% 78% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.89% 78% C+ 70% C-
Trailing 12 Months  
Capital Gain 6.30% 54% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.30% 51% F 50% F
Trailing 5 Years  
Capital Gain 104.00% 64% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.00% 64% D 47% F
Average Annual (5 Year Horizon)  
Capital Gain 11.38% 71% C- 66% D+
Dividend Return 11.38% 69% C- 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.22% 52% F 84% B
Risk Adjusted Return 86.11% 83% B 87% B+
Market Capitalization 0.48B 59% D- 47% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike